CAM
NMRA icon

Cormorant Asset Management’s Neumora Therapeutics NMRA Stock Holding History

Cormorant Asset Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-92,293
Closed -$1.57M – 60
2023
Q4 		$1.57M Hold
92,293
– – 0.08% 48
2023
Q3 		$1.3M Buy
+92,293
New +$1.15M 0.08% 46

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cormorant Asset Management's NMRA Position: Q1 2024 in Review

Cormorant Asset Management sold out of Neumora Therapeutics (NMRA) in Q1 2024, closing a stake of 92,293 shares — an estimated $1.57M sold.

Cormorant Asset Management first reported a position in NMRA in Q3 2023 and held it in 2 quarters. The position peaked at $1.57M in Q4 2023. 88 funds tracked by Wall St. Rank hold NMRA as of Q1 2024.

  • Cormorant Asset Management reported no remaining Neumora Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 92,293 Neumora Therapeutics shares in Q1 2024, an estimated $1.57M.
  • Cormorant Asset Management first reported a position in Neumora Therapeutics in Q3 2023 and held it in 2 quarters.
  • Cormorant Asset Management's Neumora Therapeutics position peaked at $1.57M in Q4 2023.
  • 88 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2024.

Based on Cormorant Asset Management's 13F filing for Q1 2024, filed 15 May 2024.